Introduction
============

Esophageal cancer is the 6^th^ most common cause of cancer deaths worldwide [@B1] and it is an endemic in many parts of the world, particularly in the developing countries, including China [@B2], [@B3]. Histologically, esophageal cancer can be classified as adenocarcinoma and esophageal squamous cell carcinoma (ESCC) which is the most common histology in Asia [@B4]. For locally advanced or metastatic ESCC patients, chemotherapy can improve overall survival (OS) and progression free survival (PFS) [@B5]. Cisplatin (DDP) is one of the most active agents with a single-agent response rate of about 20% [@B6]. One of the most important problems in the treatment of ESCC is the intrinsic/acquired resistance to platinum derivatives (DDP, CBDCA and L-OHP) [@B7]^.^ Knowledge of the active mechanism of resistance may lead to new treatment strategies by overcoming platinum-resistance and by selection of platinum-resistance patients for specific treatment modalities, then improve OS of patients with ESCC.

In vitro, the major mechanisms of resistance to platinum include decreased drug accumulation, enhanced detoxification, and increased DNA repair efficiency [@B8]-[@B10]. Among these, reduced cellular drug accumulation is the most universally identified mechanism of acquired platinum resistance [@B11]-[@B13]. Multidrug resistance (MDR) has been noted as an important mechanism of drug resistance in tumor cell lines. ATP binding cassette transporters are implicated in MDR phenotypes of tumor cells [@B14] and can reduce cellular drug accumulation. MDR1 gene encodes for P glycoprotein (P-gp), which plays an important role in the bioavailability and cell-toxicity limitation of a wide range of drugs and xenobiotics [@B15]. The multidrug resistance-associated protein 1 (MRP1, or ABCC1), lung resistance protein (LRP, or MVP), the ATP-binding cassette, sub-family G member 2 protein (ABCG2, or BCRP) were association with the multidrug-resistance in the ESCC cell lines [@B16]. Increasing cytoplasmic constituents, including the abundant nucleophilic GSH catalyzed by GSH-S-transferase (GST) and the cysteine-rich metallothionein enhanced platinum\'s detoxification and induced platinum resistance. Qiang, F [@B17] reported that the design and application of chemotherapeutic protocols capable of reducing GST-pi expression might be beneficial for patients with ESCC. In addition, increased DNA repair is another factor that might confer platinum resistance, such as DNA polymerase beta (DNA polβ) could bypass other DNA damage adducts in vitro, including platinum-induced intra-strand adducts [@B18].

As an essential trace element and catalytic factor for many enzymes, copper plays an important role in human physiology and metabolism. Its homeostasis is tightly regulated by many factors including copper uptake, intracellular distribution, and copper export. The three processes are mediated through the coordinated action of the copper uptake protein Ctr1, the copper export proteins ATP7A and ATP7B. Recent reports showed that import and export copper transporters were also involved in the transport of platinums. Cells selected for DDP-resistance are cross-resistant to Cu, and vice versa [@B19]. Ctr1 has been convincingly demonstrated to transport cisplatin and its analogues, such as carboplatin and oxaliplatin. Yeast, mouse and human cells lacking Ctr1 display decreased cisplatin accumulation and increased cisplatin resistance [@B20], [@B21]. Evidences also suggest that the two copper efflux transporters ATP7A and ATP7B regulate the efflux of DDP [@B12], [@B22]. Recently, we found that ATP7A was associated with platinum-resistance in non-small cell lung cancer (NSCLC) [@B22]. ATP7B, another copper efflux transporter, has also implicated in platinum-resistance [@B23], [@B24].

Whether ESCC cells share common drug resistance mechanisms with other cancers or possess their own distinct characteristics is still in doubt. Hence, knowledge of the active mechanism of platinum resistance in ESCC may lead to new treatment strategies and allow the selection of patients for specific treatment modalities

Materials and Methods
=====================

Drugs
-----

DDP and CBDCA were purchased from Bristol-Myers Squibb (NY, USA), and L-OHP was provided by Sanofi-aventis (Paris, France). DDP was stored as a 3.3 mM stock solution in 0.9% NaCl in the dark at room temperature, CBDCA was stored as a 27 mM stock solution in water at 4℃, and L-OHP was stored as a 12.6 mM stock solution in water at -20℃.

Cell lines and cell culture
---------------------------

Esophageal squamous cell cancer (ESCC) cell line EC109 and its DDP-resistant subline EC109/DDP were all cultured in the Dulbecco\'s modified Eagle\'s medium (DMEM) (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen, CA, USA), 100 U/ml penicillin (Tianxin, Guangzhou, China) and 100 U/ml streptomycin (Merro,Dalian, China) in a humidified incubator containing 5% CO2 at 37°C.

MTT assay
---------

The cytotoxicities of DDP, CBDCA and L-OHP were determined using the MTT assay. Monodispersed cells in the exponential growth phase were plated in 200 μl of medium per well in 96-well plates. After overnight incubation, medium without drug was added to the control and blank wells, and medium in other wells was removed and replaced by various concentrations of the drugs mentioned above. Eight different concentrations for each drug were analyzed, and three wells were used for each determination. After a 72 hour- incubation, 20 ul of MTT (5mg/ml phosphate-buffered saline) was added to each well and incubated for an additional 4 h. After aspiration of the culture medium, the resulting formazan was dissolved with 100 ul of dimethylsulfoxide (DMSO). After shaking for 10 min, 96-well plates were read at 570 and 630 nm using an enzyme-linked immunosorbent assay reader (Thermo Labsystems, Franklin, Massachusetts, USA). According to these results, the dose-response curve could be plotted, from which the inhibitory concentration that killed 50% of cell population (IC50) was derived. Resistance index (RI) was calculated as IC50 resistant /IC50 sensitive cell line. Experiments were performed in triplicate.

Semi-quantitative RT-PCR
------------------------

The mRNA expression of multidrug resistance-related genes, MDR, MRP1, ABCG2, LRP, GST-pi, DNApolβand copper transporters (CTR1, ATP7A and ATP7B) were determined using semi-quantitative RT-PCR. Total RNA was isolated from EC109, EC109/DDP cells using Trizol reagent (Invitrogen, CA, USA) according to the manufacturer\'s instructions. RNA was quantified spectrophotometrically by Nucleic Acid/Protein Analyzer DU 800 (Beckman Coulter, CA, USA). Total RNA was reverse-transcribed using the First Strand cDNA Synthesis Kit (Promega, WI, USA). 15 μl reaction volume containing 2 μg RNA and 1 μl oligo (dT)~15~ Primer was denatured at 70°C for 5 min and then quickly chilled on ice. To synthesize cDNA, a reaction mixture was added to the denatured RNA so that the final 25 μl reaction volume containing 5 μl 5×RT Buffer (containing 25mM Mg2+), 1 μl RNase Inhibitor (10 U/μl), 1 μl Moloney murine leukemia virus reverse transcriptase (100 U/μl), and 1 μl dNTP mixture (each 10mM). The reaction was incubated at 37°C 60 min. Then cDNA (2 μl) was then amplified by PCR using 12.5 μl 2×GoTaq Green Master Mix (Promega, WI, USA), 2.5 μl upstream primers, 2.5 μl downstream primer (10 mM for each primer) and 5.5 μl Nuclease-Free Water with the total volume of 25 μl. The primers were synthesized according to previous reports \[26; 27; 28; 29\] or designed using the Primer Express® program (Applied Biosystems). The primers sequences, gene bank accession number, annealing temperature and length of products were listed in table [1](#T1){ref-type="table"}. GAPDH was used as an internal control. Aliquots of PCR product were electrophoresed on 1.5% agarose gels, and PCR fragments were visualized by ethidium bromide staining.

Immunoblotting
--------------

Whole-cell extracts were obtained by lysis of cells in a 2×sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis sample buffer. Equal amounts of protein (50 mg/sample as determined by UV spectrometry) were electrophoresed on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes in 25mmol/l Tris-HCl (pH 8.3) for 2 h at 100mA.The membranes were blocked with Tween Tris-buffered saline (TBS) with 5% nonfat milk and 0.1% Triton X-100 for 2 hours at room temperature and reacted with primary antibodies overnight at 4℃. Primary antibodies were diluted in a blocking solution 1: 500 for ATP7A (Abcam, Cambrige, UK) and 1 : 5000 for GAPDH (Boster, Wuhan, China). After washing with TBS Tween-20 for 30min, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h, then washed for 1 h with TBS Tween-20. Bands were developed using chemiluminescent detection reagents and signal detection and quantification were carried out with an ECL system (Amersham Biosciences, New Jersey, USA) and Image Quant analysis software Quantity One V4.62 (Bio-Rad, CA, USA).

siRNA transfection
------------------

ATP7A siRNA sequences were obtained from Ambion (Austin, TX) siRNA library (ID number 120175) and targeted exon 11 (sense, GCAACUAUUGUAACUCUUG dTdT; antisense, CAAGAGUUACAAUAGUUGC dTdT) \[30\]. A nonsilencing siRNA sequence, shown by BLAST search to not share sequence homology with any known human mRNA was used as control for ATP7A-targeting experiments. The siRNA sequences were synthesized by Guangzhou RiboBio (Ghuangzhou, China). EC109/DDP or A549/DDP cells were plated into 6-well plates as required for the experiments. The cells were allowed to adhere for overnight. The transfection of siRNA was performed using lipofectamine-2000 (Invitrogen, CA, USA) according to the manufacturer\'s recommendation. Oligofectamine /siRNA complexes were formed in serum free DMEM by adding siRNA (25, 50 or 100 nM final concentration) to 5μl of Oligofectamine (Invitrogen, CA, USA) per well. Complexes were allowed to form at 25°C for 10 min and added to wells (500 μl per well). After 4 hours of transfection, the culture medium containing 10% serum was added. The assays were carried out 24, 48, 72, 80 hours post transfection.

Flow cytometry
--------------

Apoptotic or necrotic cell death was determined by flow cytometric analysis of cells double stained with Annexin V-FITC and propidium iodide (PI) using an assay kit from KeyGen Biotech (Nanjing, China). EC109/DDP cells were plated into 6-well plates and adhered for overnight. Then 100 nM final concentration of siRNA (targeted-ATP7A or nonsilencing siRNA) was added to wells for transfection. After 4 hours of transfection and 72 hours for DDP incubation, cells were collected, washed with cold PBS, and suspended in binding buffer. The cells were stained with Annexin V-FITC and PI for 15 minutes at room temperature in the dark. The samples were analyzed with a flow cytometer (BECKMAN-COULTER FC500, CA, USA).

Results
=======

Drug sensitivities to platinum-derivatives
------------------------------------------

The drug sensitivity data of EC109 and EC109/DDP cells to three platinum-derivate drugs (DDP, CBDCA and L-OHP) was shown in Table [2](#T2){ref-type="table"}. The IC50 ranged from 2.84 to 24.13 uM for DDP, from 16.35 to 86.08 for CBDCA, and 7.11 to 29.29 for L-OHP. Compared with the parental cells, the DDP-resistant sublines (EC109/DDP) showed 8.49, 5.27 and 4.12 folds enhanced resistance to DDP, CBDCA, and L-OHP respectively.

Expression of drug resistance-related genes
-------------------------------------------

Gene expression analysis of MDR1, ABCG2, MRP1, LRP, DNApolβ, GST-pi, CTR1, ATP7A and ATP7B in mRNA were shown in Figure [1](#F1){ref-type="fig"}a. After normalizing the mRNA expression level of each gene relative to GAPDH expression, we compared the expressions of drug resistance-related genes in resistant sublines (EC109) to their drug-sensitively parental cell lines (EC109/DDP) respectively. Between EC109 and EC109/DDP cells, there was no difference in the expression of ABCG2, MRP1, LRP, DNApolβ, GST-pi, CTR1 and ATP7B, but ATP7A mRNA expressions in EC109/DDP cell was significantly higher than in the parental cells. Surprisingly, MDR1 mRNA expression was significantly lower in EC109/DDP cells as compared to EC109 cells. Using RT-PCR, we found that copper transporter ATP7A mRNA expressions in EC109/DDP cells was much higher than in EC109 cells. Furthermore, we analyzed the ATP7A protein expression in these two kinds of cells with Western-Blot (Figure [1](#F1){ref-type="fig"}b). After normalizing the protein expression level of ATP7A relative to GAPDH, ATP7A protein expression was much higher in EC109/DDP than in EC109 cells (Supplementary figure [1](#SM1){ref-type="supplementary-material"}). These results indicated that ATP7A may be related to the platinum-derivates resistance in EC109/DDP cells.

SiRNA targeting ATP7A decreases the expressions of ATP7A protein in DDP-resistant cancer cells
----------------------------------------------------------------------------------------------

To determine whether or not knockdown the expression of ATP7A could reverse the platinum-resistance of EC109/DDP cells, we used RNA interference system to explore the role of ATP7A in platinum resistance. As shown in Figure [2](#F2){ref-type="fig"}, ATP7A expressions in EC109/DDP cells changed after treatment with different final concentration of ATP7A-targeted siRNA sequences (25nM, 50nM and 100nM) for 80h. 25 nM ATP7A-targeted siRNA sequences have no effects on the expressions of ATP7A protein in the DDP-resistant cancer cells, and 50nM ATP7A-targeted siRNA sequences partially knockdown the expressions of ATP7A protein in EC109/DDP cells. In the treatment of 100nM ATP7A-targeted siRNA sequences, the expressions of ATP7A protein in EC109/DDP cells were almost silenced (83.0%). The expression of control protein, GAPDH, was unaffected by ATP7A-targeted siRNA treatment. 100nM nonsilencing siRNA sequence as control siRNA had absolutely no effect on the levels of ATP7A or GAPDH in EC109/DDP cells. Based on the results, 100nM ATP7A-targeted siRNA sequences were enough and specific to remarkably decrease the expression of ATP7A protein in EC109/DDP cells.

Effect of RNAi targeting ATP7A on chemosensitivity to DDP in EC109/DDP cells
----------------------------------------------------------------------------

EC109/DDP cells were transiently transfected with ATP7A-targeted siRNA 100 nM for 8 h, then cells were exposed to DDP for another 72 h. MTT assay was employed to investigate the reversal effect of siRNA transfection (100nM, 80h) on the DDP-resistance of EC109/DDP cells. The results were shown in Table [3](#T3){ref-type="table"}. Experimental data showed that siRNA transfection targeting ATP7A significantly reduced IC50 of EC109/DDP cells compared with controls (reversal effect of 37.09%). Silencing ATPA was able to partially reverse DDP-resistance in EC109/DDP cells. These results indicated that ATP7A played an important role in the modulation of platinum-resistance in EC109/DDP cells.

RNAi targeting ATP7A increased apoptotic rate in EC109/DDP
----------------------------------------------------------

To further determine whether ATP7A-targeted siRNA transfection could effectively reverse the platinum-resistance of EC109/DDP, DDP-induced apoptosis was detected and shown as Figure [3](#F3){ref-type="fig"}. Without DDP, there were little apoptosis and no significant difference between ATP7A-targeted siRNA groups and control siRNA groups in all cells. But after adding different concentrations of DDP for 72h, ATP7A-targeted siRNA groups\' cells apoptotic rates were significantly higher than control siRNA groups (39.0±2.17% VS 17.2±1.40% at 25 uM DDP and 62.1±1.76% VS 44.4±2.01% at 50 uM DDP). So siRNA transfection targeting ATP7A significantly enhanced DDP-inducing apoptosis compared with siRNA-control at different DDP concentrations (P \< 0.01). These results showed the potential mechanism of ATP7A in the modulation of platinum resistance.

Discussion
==========

This article sheds light on the potential cellular functions of copper transporter ATP7A for platinum-resistance in ESCC.

In our study, DDP-resistant cell sublines (EC109/DDP) are 8.49 folds resistant to DDP than the parental cells (EC109 lines), and both exhibit cross-resistance to CBDCA (5.27 folds) and L-OHP (4.12 folds), to which they were not previously exposed, indicating they were multidrug-resistant cell lines.

Although the mRNA expression of ABCG2, MRP1, LRP, GST-pi, CTR1, and ATP7B between EC109/DDP and EC109 cells was similar, MDR1 expression significantly decreased in EC109/DDP cells compared with EC109 cells which was consistent with the result reported by Wen J [@B16], who established the EC109/DDP subline. It seemed that the mechanisms of platinum resistance in EC109/DDP cells might be independent of ABC transporters. Previous reports showed that increased drug efflux and lowered intracellular drug concentration both contributed to MDR, in which ATP-binding cassette (ABC) transporters including MDR1, MRP1, and ABCG2 and LRP [@B25] were the most prominent. But in general, platinum drugs are not transported by ABCB1, ABCC1 or ABCG2 [@B26], [@B27]. But mRNA did not always parallel with protein expression or activity. Protein level and/or activity of ABC transporters, but not mRNA level may determine drug resistance.

We found that ATP7A expression in both mRNA and protein levels significantly increased in EC109/DDP cells compared to the parental cells respectively. Moreover, in EC109/DDP cells, ATP7A siRNA knockdown (83.0%) was able to partially reverse DDP-resistance (37.09%). As the cytotoxicity of platinum compounds was thought to be determined primarily by their DNA adducts, which could then induce cells apoptosis. In our study, silencing of ATP7A increased cells apoptosis rate in EC109/DDP, so reduced expression of ATP7A by siRNA knockdown resulted in enhancement of DDP-sensitivity and increased DDP-induced apoptosis. These results indicated that ATP7A played an important role in the modulation of platinum resistance in EC109/DDP cells. Overexpression of ATP7A in EC109/DDP cells might increase pumping platinum out of cells or binding and sequestration of platinum drugs, then decrease cellular platinum concentration or keep them away from accessing their key cytotoxic targets in the nucleus, finally result in DDP-resistance [@B28], [@B29].

Recent studies showed that import and export copper transporters were also involved in platinum-resistance in some cancers [@B28], [@B30]. As a catalytic factor for many enzymes, copper stimulates the proliferation and migration of endothelial cells and is required for the secretion of several angiogenic factors by tumor cells, such as VEGF, therefore it plays an important role in angiogenesis. Thus, silencing the copper transporters resulting in copper level change which may have an additional benefit to reduce angiogenesis [@B12]. Some studies have demonstrated that transporters controlling copper influx, especially Ctr1, are involved in the cellular uptake of DDP [@B31]. Holzer et al. [@B31] reported that knock-out of Ctr1 in murine embryonic fibroblasts led to reduced uptake of DDP, CBDCA and to a lesser extent of L-OHP. And there have been few reports about copper transporters CTR1 in the small cell lung cancers (SCLC) for the DDP and CBDCA resistance [@B21]. Using Confocal microscopic analysis, Katano, K et al also found ATP7B mediated resistance to DDP by sequestering it into vesicles of the secretory pathway for export from the resistant ovarian cell lines [@B32], [@B33]. ATP7A is overexpressed in some DDP-resistant ovarian carcinoma cell lines [@B34], and Samimi G also demonstrated that Human ovarian carcinoma cells transfected with an ATP7A-expression construct also conferred resistance to DDP, CBDCA, and L-OHP by sequestering platinum analogues in intracellular compartments and preventing their reaction with nuclear DNA [@B10], [@B35]. Plasencia, C also reported that ATP7A was overexpressed in the L-OHP resistant colorectal cancer cells [@B36], and Kitada, N demonstrated that ATP7A mRNA was a factor affecting the cytotoxicity of cisplatin and oxaliplatin [@B37]. Our previous study had found that overexpression of ATP7A played an important role in platinum-resistance of NSCLC, and was a negative prognostic factor of NSCLC patients treated with platinum-based chemotherapy [@B30]. But Mangala, LS reported that silencing of ATP7A gene had no significant effect on the sensitivity of resistant cells to DDP, while ATP7B silencing resulted in partial enhancement of DDP-sensitivity and increased DNA adduct formation in cisplatin-resistant ovarian cells [@B38]. But there are no reports about the copper transports in the ESCC patients. As we known, this is the first time study to analyze copper transporters in ESCC cell lines.

Drug resistance is a multi-factorial problem. In our study, efficient down-regulation of ATP7A in EC109/DDP cells could not reverse DDP-resistance completely, indicating that there could be some other important mechanisms accounting for the drug resistant phenotype. Furthermore, the interaction between ATP7A and platinum remains unknown. Does ATP7A transfer intracellular platinum into the vesicular secretory pathway for exporting from the cell, or sequestrating platinum from its targets as one of the components in the cellular platinum detoxification mechanism? Of note, most of these data are derived from in vitro drug-exposed tumor cells while the resistance mechanisms in patients are by far less well understood.

In conclusion, as first evidence, our results collectively indicate that overexpression of copper efflux transporter ATP7A is responsible for platinum resistance in EC109/DDP cells. These studies may ultimately lead to a better utilization of platinum-based antitumor agents and thereby improve the chemotherapeutic efficacy in ESCC patients.
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![Expression of drug resistance-related genes (MDR1, ABCG2, ABCC1, LRP, DNA polβ, GSTpi, CTR1, ATP7A and ATP7B) in EC109 and EC109/DDP. a). Total RNA isolated from EC109 and EC109/DDP cells was subjected to RT-PCR for the indicated nuclear genes, as described in Materials and Methods. Reaction products were analyzed on an agarose gel and visualized by ethidium staining. b). ATP7A protein expression was determined by Western blot analysis using anti-ATP7A antibody.](jcav07p2085g001){#F1}

![Effect of ATP7A-siRNA 80h on ATP7A\'s protein expression in DDP-resistant cell sublines (EC109/DDP).](jcav07p2085g002){#F2}

![Increasing DDP induced apoptosis after ATP7A\'s silence for 80 h by siRNA in A549/DDP cells.](jcav07p2085g003){#F3}

###### 

Primers used for RT-PCR analysis.

  Gene       Primers (5\'→3\')          Gene bank accession number   Annealing Temperature(°C)   Size (bp)
  ---------- -------------------------- ---------------------------- --------------------------- -----------
  MDR1                                  NM_000927.3                  58                          154
  forward    ATATCAGCAGCCCACATCAT                                                                
  reverse    GAAGCACTGGGATGTCCGGT                                                                
  MRP1                                  NM_019898.2                  60                          181
  forward    ATCAAGACCGCTGTCATTGG                                                                
  reverse    GAGCAAGGATGACTTGCAGG                                                                
  ABCG2                                 NM_004827.2                  60                          172
  forward    TGCCCAGGACTCAATGCAACAG                                                              
  reverse    ACAATTTCAGGTAGGCAATTGTG                                                             
  LRP                                   NM_017458.2                  53                          240
  forward    GTCTTCGGGCCTGAGCTGGTGTCG                                                            
  reverse    CTTGGCCGTCTCTTGGGGGTCCTT                                                            
  GST pi                                NM_000852.3                  46.5                        399
  forward    CCTACACCGTGGTCTATTTC                                                                
  reverse    GGGACAGCAGGGTCTCAA                                                                  
  DNA polβ                              NM_002690.1                  42                          139
  forward    TGCCTGGAGTAGGAACA                                                                   
  reverse    GGACCAATGCCACTAAC                                                                   
  CTR1                                  NM_001859.3                  54                          445
  forward    AGCTATATGGACTCCAACAG                                                                
  reverse    CGTTGTAGGTCATGAAGATG                                                                
  ATP7A                                 NM_000052.4                  54                          175
  forward    GCCTGCGTACGTGGATTTAT                                                                
  reverse    TCAATGGTCCAAACACAGGA                                                                
  ATP7B                                 NM_000053.2                  42                          407
  forward    GGGGTGTAGGTTCTCGC                                                                   
  reverse    TGCTCCCAAAGGGTTCT                                                                   
  GAPDH                                 NM_002046.3                  50                          358
  forward    CGGGAAGCTTGTCATCAATGG                                                               
  reverse    GGCAGTGATGGCATGGACTG                                                                

###### 

Drug sensitivity of EC109 and EC109/CDDP cells to platinum derivatives (CDDP, CBDCA and L-OHP).

          IC50 (mean±SD, uM)                       
  ------- -------------------- ------------ ------ ---------
  DDP     2.84±0.10            24.13±1.47   8.49   \<0.001
  CBDCA   16.35±0.49           86.08±1.88   5.27   \<0.001
  L-OHP   7.11±0.49            29.29±1.20   4.12   \<0.001

###### 

Partially reversal effect after ATP7A\'s silence by siRNA for 80h in the DDP-resistant sublines (EC109/DDP).

  cell lines                IC~50~(mean±SD,uM)   reversal effect (%)   P
  ------------------------- -------------------- --------------------- ---------
  EC109/DDP Control SiRNA   24.10±1.01                                 
  EC109/DDP ATP7A SiRNA     15.16±0.24           37.09                 \<0.001
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